Antibody–drug conjugates: an emerging concept in cancer therapy RVJ Chari, ML Miller, WC Widdison Angewandte Chemie International Edition 53 (15), 3796-3827, 2014 | 1030 | 2014 |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same RY Zhao, ML Miller, WC Widdison, RVJ Chari US Patent 6,716,821, 2004 | 357 | 2004 |
Disulfide-linked antibody− maytansinoid conjugates: Optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage BA Kellogg, L Garrett, Y Kovtun, KC Lai, B Leece, M Miller, G Payne, ... Bioconjugate chemistry 22 (4), 717-727, 2011 | 253 | 2011 |
Benzodiazepine derivatives W Li, N Fishkin, R Zhao, M Miller, R Chari US Patent 8,426,402, 2013 | 182 | 2013 |
Chemistry and chemical biology of taxane anticancer agents ML Miller, I Ojima The Chemical Record 1 (3), 195-211, 2001 | 172 | 2001 |
Synthesis and structure-activity relationships of new second-generation taxoids I Ojima, T Wang, ML Miller, S Lin, CP Borella, X Geng, P Pera, ... Bioorganic & medicinal chemistry letters 9 (24), 3423-3428, 1999 | 137 | 1999 |
Design, synthesis, and biological evaluation of new-generation taxoids I Ojima, J Chen, L Sun, CP Borella, T Wang, ML Miller, S Lin, X Geng, ... Journal of medicinal chemistry 51 (11), 3203-3221, 2008 | 129 | 2008 |
Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use RVJ Chari, ML Miller US Patent 6,596,757, 2003 | 115 | 2003 |
Macrocycle formation by ring-closing metathesis. Application to the syntheses of novel macrocyclic taxoids I Ojima, S Lin, T Inoue, ML Miller, CP Borella, X Geng, JJ Walsh Journal of the American Chemical Society 122 (22), 5343-5353, 2000 | 113 | 2000 |
Folate receptor–specific antitumor activity of EC131, a folate-maytansinoid conjugate JA Reddy, E Westrick, HKR Santhapuram, SJ Howard, ML Miller, M Vetzel, ... Cancer Research 67 (13), 6376-6382, 2007 | 112 | 2007 |
A new class of antibody–drug conjugates with potent DNA alkylating activity ML Miller, NE Fishkin, W Li, KR Whiteman, Y Kovtun, EE Reid, KE Archer, ... Molecular Cancer Therapeutics 15 (8), 1870-1878, 2016 | 107 | 2016 |
Methods of preparation of conjugates N Fishkin, M Miller, W Li, R Singh US Patent 9,353,127, 2016 | 74 | 2016 |
Synthesis of novel C2− C3 ‘N-linked macrocyclic taxoids by means of highly regioselective Heck macrocyclization X Geng, ML Miller, S Lin, I Ojima Organic Letters 5 (20), 3733-3736, 2003 | 65 | 2003 |
Design, synthesis and structure− activity relationships of novel taxane-based multidrug resistance reversal agents I Ojima, CP Borella, X Wu, PY Bounaud, CF Oderda, M Sturm, ML Miller, ... Journal of medicinal chemistry 48 (6), 2218-2228, 2005 | 57 | 2005 |
A DNA-interacting payload designed to eliminate cross-linking improves the therapeutic index of antibody–drug conjugates (ADCs) ML Miller, M Shizuka, A Wilhelm, P Salomon, EE Reid, L Lanieri, S Sikka, ... Molecular Cancer Therapeutics 17 (3), 650-660, 2018 | 53 | 2018 |
Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery ML Miller, EE Roller, RY Zhao, BA Leece, O Ab, E Baloglu, ... Journal of medicinal chemistry 47 (20), 4802-4805, 2004 | 53 | 2004 |
Cytotoxic benzodiazepine derivatives W Li, M Miller, N Fishkin, RVJ Chari US Patent 8,765,740, 2014 | 52 | 2014 |
Cytotoxic benzodiazepine derivatives W Li, ML Miller, NE Fishkin, RVJ Chari US Patent 8,889,669, 2014 | 51 | 2014 |
Benzodiazepine derivatives W Li, NE Fishkin, RY Zhao, ML Miller, RVJ Chari US Patent 8,802,667, 2014 | 46 | 2014 |
Optimizing Lysosomal Activation of Antibody–Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers PL Salomon, EE Reid, KE Archer, L Harris, EK Maloney, AJ Wilhelm, ... Molecular pharmaceutics 16 (12), 4817-4825, 2019 | 39 | 2019 |